proline, histidine and glycine rich 1Genealiases: []
Q-omics provides the consensus-scored PHGR1 profile across patient tissues and cancer cell-line models. PHGR1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PHGR1 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, PHGR1 RNA expression shows 14,416 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight BRCA, COAD, and ESCA as cancer lineages where PHGR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHGR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHGR1 survival associations across molecular data types. PHGR1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHGR1 RNA expression–survival associations across cancer types. High PHGR1 expression shows unfavorable associations in UCEC, UVM and ESCA, but favorable associations in BRCA, BLCA and CHOL. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for PHGR1 RNA expression.
This table summarizes PHGR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PHGR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHGR1 shows lower tumor expression in COAD and STAD and higher tumor expression in KIRC, PRAD, LIHC and KICH. The COAD box plot shows higher PHGR1 RNA expression in normal versus tumor tissue (log2 FC = −1.996, t-test p < 0.001).
This table shows molecular features associated with PHGR1 in patient tissues and cancer cell lines. In patient samples, PHGR1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, PHGR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS.
